Literature DB >> 19563838

Do diabetes drugs modify the risk of pancreatic cancer?

Yu-Xiao Yang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19563838     DOI： 10.1053/j.gastro.2009.06.022

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  13 in total

Review 1.  Metformin and cancer.

Authors:  Natalia G Vallianou; Angelos Evangelopoulos; Christos Kazazis
Journal:  Rev Diabet Stud       Date:  2014-02-10

2.  Metformin use is associated with better survival of diabetic patients with pancreatic cancer.

Authors:  Navid Sadeghi; James L Abbruzzese; Sai-Ching J Yeung; Manal Hassan; Donghui Li
Journal:  Clin Cancer Res       Date:  2012-03-31       Impact factor: 12.531

3.  Medically managed hypercholesterolemia and insulin-dependent diabetes mellitus preoperatively predicts poor survival after surgery for pancreatic cancer.

Authors:  Ryaz B Chagpar; Robert C G Martin; Syed A Ahmad; Hong Jin Kim; Christopher Rupp; Sharon Weber; Andrew Ebelhar; Juliana Gilbert; Adam Brinkman; Emily Winslow; Clifford S Cho; David Kooby; Carrie K Chu; Charles A Staley; Kelly M McMasters; Charles R Scoggins
Journal:  J Gastrointest Surg       Date:  2011-02-15       Impact factor: 3.452

4.  Antidiabetic Drug Metformin Prevents Progression of Pancreatic Cancer by Targeting in Part Cancer Stem Cells and mTOR Signaling.

Authors:  Altaf Mohammed; Naveena B Janakiram; Misty Brewer; Rebekah L Ritchie; Anuj Marya; Stan Lightfoot; Vernon E Steele; Chinthalapally V Rao
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

5.  Islet inflammation and ductal proliferation may be linked to increased pancreatitis risk in type 2 diabetes.

Authors:  Belinda Schludi; Abu Saleh Md Moin; Chiara Montemurro; Tatyana Gurlo; Aleksey V Matveyenko; David Kirakossian; David W Dawson; Sarah M Dry; Peter C Butler; Alexandra E Butler
Journal:  JCI Insight       Date:  2017-07-06

6.  Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals.

Authors:  Meei-Shyuan Lee; Chih-Cheng Hsu; Mark L Wahlqvist; Hsin-Ni Tsai; Yu-Hung Chang; Yi-Chen Huang
Journal:  BMC Cancer       Date:  2011-01-18       Impact factor: 4.430

Review 7.  Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis.

Authors:  Zhi-Jiang Zhang; Zhi-Jie Zheng; Haidong Kan; Yiqing Song; Wei Cui; Genming Zhao; Kevin E Kip
Journal:  Diabetes Care       Date:  2011-10       Impact factor: 19.112

Review 8.  Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis.

Authors:  Hiroshi Noto; Atsushi Goto; Tetsuro Tsujimoto; Mitsuhiko Noda
Journal:  PLoS One       Date:  2012-03-20       Impact factor: 3.240

9.  Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?

Authors:  P C Butler; A V Matveyenko; S Dry; A Bhushan; R Elashoff
Journal:  Diabetologia       Date:  2009-11-06       Impact factor: 10.122

Review 10.  Low-carbohydrate diets and all-cause mortality: a systematic review and meta-analysis of observational studies.

Authors:  Hiroshi Noto; Atsushi Goto; Tetsuro Tsujimoto; Mitsuhiko Noda
Journal:  PLoS One       Date:  2013-01-25       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.